Samaritan CEO Provides Wall Street Transcript Update on Its Most Advanced Drug Discovery and Development Programs

Samaritan CEO Provides Wall Street Transcript Update on Its Most Advanced Drug Discovery and Development Programs

Business Wire - November 17, 2005

LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its CEO Dr. Janet Greeson recently granted the Wall Street Transcript an exclusive interview profiling Samaritan, and an update on its most recent corporate accomplishments, including discussions on the following topics:

-- What has enabled you to do so much with so little?

-- If all goes as it should, what will make your HIV drug superior?

-- What is the timetable?

-- Would you be profitable by 2009 or 2010?

-- What would be the two or three best reasons for the long-term investor to look closely at Samaritan?

To read the in-depth interview on Samaritan, visit

http://www.samaritanpharma.com/images/twstnovember05.pdf

Samaritan Pharmaceuticals: "We LIV...to Save Lives."

Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative drugs. Samaritan, in collaboration with Georgetown University, is advancing 8 promising compounds, out of its pipeline of 250 possible drug candidates; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

CONTACT: Samaritan Pharmaceuticals, Inc.

Gene Boyle, 702-735-7001, GeneBoyle@SamaritanPharma.com

SOURCE: Samaritan Pharmaceuticals Inc.

051117
BW051110

Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .